GENE ONLINE|News &
Opinion
Blog

2022-08-17| M&A

Bristol Myers Squibb Completes Third Largest Acquisition of 2022

by Max Heirich
Share To

On August 17, Bristol Myers Squibb announced its acquisition of Turning Point Therapeutics closed successfully. Bristol Myers Squibb purchased each share of Turning Point at $76, resulting in a total payment of $4.1 billion. Turning Point’s acquisition by Bristol Myers Squibb marks what is currently the third largest acquisition in the biotech industry in 2022.

Related Article: GSK’s Second Billion Dollar Acquisition Outprices their First of 2022

$4.1 billion for a Portfolio of Investigational Medicines

Turning Point Therapeutics is a clinical-stage precision oncology company possessing a pipeline of investigational medicines. These medicines address common mutations in cancers that current treatments fail to address.

Turning Point’s flagship asset is repotrectinib, a kinase inhibitor. Repotrectinib prevents oncogenic drivers, mutations responsible for both the initiation and maintenance of cancer, in non-small cell lung cancer and other solid tumors.

The Phase 1/2 TRIDENT-1 clinical trial observed repotrectinib’s long response time with oncogenic drivers. The U.S. Food and Drug Administration (FDA) granted three Breakthrough Therapy Designations for repotrectinib.

Due to the promising results of repotrectinib’s trials and the other treatments possessed by Turning Point, Bristol Myers Squibb sought to acquire the company and their portfolio. 

The Third Largest Acquisition of 2022 So Far

Initially announced in June, Bristol Myers Squibb and Turning Point’s board of directors unanimously approved the acquisition. 

As of August 15, the deal closed, with Bristol Myers Squibb paying $4.1 billion. As a result, public trading of Turning Point shares on the NASDAQ Global Select Market ceased with the deal’s completion. Now, Bristol Myers Squibb wholly owns the oncology company. The value of each of the 41,896,678 shares of Turning Point was $55.

On the completion of the acquisition, Elizabeth Mily, Executive Vice President, Strategy & Business Development at Bristol Myers Squibb, said, “Turning Point has distinguished itself in the field of precision oncology, and this acquisition will further strengthen our leading oncology franchise.”

This transaction marks yet another massive purchase within the biotech industry in 2022. Just the day before Bristol Myers Squibb’s announcement, GSK announced their own completed acquisition of Affinivax. The value of that transaction was $2.1 billion, with GSK paying $55 per outstanding share of the company. 

In the future, Bristol Myers Squibb expects the FDA to approve repotrectinib in the second half of 2023. The company hopes the treatment becomes a new standard of care for cancer patients affected by oncogenic drivers.

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
PDS Buys IL-12 Targeting Therapy From Merck KGaA for $121 Million Biobucks
2023-01-04
GeneOnline’s Pick: Top 10 M&A Deals in 2022
2022-12-28
Antengene To Pair CD73 Inhibitor With Merck’s Keytruda In Clinical Collaboration
2022-12-27
LATEST
Junshi’s PD-1 Antibody Meets Endpoint In Phase 3 Lung Cancer Trial
2023-01-19
Moderna Welcomes Phase 3 Win For RSV Vaccine
2023-01-18
Moving Beyond COVID With mRNA Technology
2023-01-18
Rob Knight and Jing-Yuan Fu Elaborate On Microbiome Research Trends at the 7th Asia Microbiome Conference(AMC)
2023-01-17
CARsgen Taps Huadong to Commercialize Multiple Myeloma CAR-T in China
2023-01-17
Scientists Study Imaging Probes in First-Ever Amputated Human Limb Model
2023-01-16
EMA Plans to Issue Liver Failure Warning for Novartis’ Gene Therapy
2023-01-16
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!